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Abstract
There has been controversy regarding the mortality directly
attributed to Acinetobacter baumannii infections. Data from six
case–control studies have been recently added to the literature
regarding the attributable mortality of A. baumannii infections
during the past months. The information from these studies, added
to the previous knowledge on this issue, provides evidence that A.
baumannii  infections are indeed associated with increased
mortality. In addition, there is relevant evidence from studies
examining the effect of inappropriate treatment on mortality;
specifically, inappropriate treatment of A. baumannii infections has
been associated with excess mortality. We believe that the
accumulated data suggest that attributable mortality due to A.
baumannii  infections should no longer be a controversial issue.
The efforts of the scientific community interested in this pathogen
should therefore be directed to the development and introduction
of new antibiotics effective against multidrug-resistant and
pandrug-resistant A. baumannii as well as the implementation of
infection control measures that may help us in the control of the
increasing problem of A. baumannii infections.
Infections due to Acinetobacter baumannii have been
frequently considered by clinicians and researchers not to be
associated with considerable mortality [1]. Indeed,
A. baumannii  has been placed in the list of low-virulence
pathogens [2]. These beliefs have generated relative wide-
spread beliefs among members of the medical community
that this microorganism is not a cause of considerable
mortality in hospitalized patients, and have generated contro-
versy on the issue of attributable mortality of A. baumannii
infections [1,3]. We recently performed a systematic review
of the literature of cohort and case–control studies that
focused on the issue [4]. The reviewed data suggest that
infection with A. baumannii is associated with considerable
mortality. In addition, we provided data regarding the impact
of inappropriate empirical treatment of A. baumannii
infections [5].
During the first 3 months of 2007, four new studies were
added to the relevant literature. Specifically, investigators
from the United States of America [6], Israel [7], Australia [8]
and Korea [9] have provided their findings regarding the
effect of A. baumannii infections in patients treated in the
intensive care unit setting and also on medical and surgical
wards. Another recent study from Israel compared A.
baumannii  bacteremia with Klebsiella pneumoniae
bacteremia [10]. We summarize the findings of these five
newer studies in Table 1.
The result of the main analysis of the latter study showed that
A. baumannii remained significantly associated with mortality
after adjustment for other important risk factors was
performed [10]. Subgroup analyses in the same study again
confirmed the association of A. baumannii with increased
mortality in those patients not mechanically ventilated in the
30 days prior to bacteremia (multivariate analysis: odds
ratio = 3.98, 95% confidence interval = 1.25–12.62) and in
those patients not presenting with septic shock (odds ratio =
4.62, 95% confidence interval = 1.74–12.22).
In addition, in a recent letter to the editor, the summary
findings of an older case–control study was reported that
compared patients who were colonized or infected with multi-
drug-resistant  A. baumannii with patients who were
colonized or infected with multidrug-resistant Pseudomonas
aeruginosa. Increased mortality was noted in the A.
baumannii group (a statistically significantly result), even after
adjusting for the stay in the intensive care unit [11].
Added to the findings of the previously available studies, we
believe that these new data clearly show that infection of
A. baumannii is associated with considerable mortality, even
after adjustment for important potential confounders such as
disease severity and the effect of the empirical antimicrobial
treatment. While one could theoretically always argue that a
specific risk factor may not have been included in the
matching process of case–control and cohort studies (and
thus differences in mortality may be attributed to this particular
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nonexamined risk factor), one has simultaneously to acknow-
ledge the hazards of adjusting to all possible factors [12].
Someone may rightfully ask why not all relevant studies
showed increased mortality of patients with A. baumannii
infections compared with controls without such infections.
There are various explanations for these apparently contro-
versial findings. These explanations may include differences
in patient populations, methodological characteristics of the
studies, proportions of patients who received appropriate
empirical treatment, as well as factors associated with the
pathogen itself, including genetic factors that lead to
differences in virulence.
If A. baumannii infection was not an independent contributor
to increased mortality, then inappropriate treatment should
not have any major effect on the outcome of patients. In an
older study, mortality due to A. baumannii bacteremia treated
with inappropriate antibiotics was 7.6% in excess (although
not a statistically significant difference) compared with that of
patients treated with appropriate antibiotics [13]. The finding
of this study has to be interpreted considering that no excess
mortality was found for any other bacteremia (possibly due to
the small number of patients) except for bacteremia due to
coagulase-negative Staphylococci [13]. In a study by our
group, inappropriate treatment of A. baumannii bacteremia
was associated with considerably increased (25.8%)
mortality compared with that of patients treated with
appropriate antibiotics – significance reached a trend
(P = 0.1) since the total study population was small (40
patients) [5].
In the recently published study by Kwon and colleagues, a
44.5% increased mortality was noted in the group of patients
with imipenem nonsusceptible A. baumannii bacteremia
treated with inappropriate antibiotics compared with those
patients with imipenem nonsusceptible A. baumannii
bacteremia who received appropriate treatment (P = 0.007)
[9]. Moreover, when 30-day mortality was examined in the
total study population of cases and controls, a 43.7% excess
mortality was noted when A. baumannii bacteremia was
treated with inappropriate versus appropriate antibiotic
therapy (P < 0.001) [9]. Also, in a study regarding risk factors
for mortality related to nosocomial pneumonia due to various
Gram-negative, Gram-positive and fungal pathogens, A.
baumannii  was the second most commonly cultured
pathogen of 132 patients. In this study A. baumannii was
significantly more predominant in nonsurvivors than in
survivors (13.6% versus 5.1%, P = 0.04). Of the
nonsurvivors, 85.9% received inappropriate therapy –
inappropriate antibiotic therapy was independently
associated with mortality (odds ratio = 14.5, 95% confidence
interval = 5.08–41.44) in the study [14].
We believe that a fair interpretation of the available evidence,
especially in light of the recently published findings, suggests
that attributable mortality due to A. baumannii is no longer a
controversial issue. The attention of the scientific community
with interest in this pathogen should therefore be directed to
the development and introduction of new antimicrobial agents
effective against multidrug-resistant and pandrug-resistant
A. baumannii, as well as to the implementation of infection
control measures that may help control the evolving problem
of A. baumannii infections that have taken epidemic dimensions
in several parts of the word, especially in critically ill patients.
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